Serum Lipidomics Profiling to Identify Biomarkers for Non-Small Cell Lung Cancer

Table 6

The detailed results of the pathway analysis by lipidomics.

Groups		Total	Hits	Raw p	-log(p)	FDR	Impact
NSCLC vs HC	Glycerophospholipid metabolism	39	3	0.00002	11.070	0.001	0.329
	Glycosylphosphatidylinositol(GPI)-anchor biosynthesis	14	1	0.023	3.769	0.659	0.044
	Linoleic acid metabolism	15	1	0.025	3.701	0.659	0.001
	alpha-Linolenic acid metabolism	29	1	0.047	3.050	0.835	0.001
	Glycerolipid metabolism	32	1	0.052	2.954	0.835	0.012
NSCLC vs LBD	Glycerophospholipid metabolism	39	2	0.001	7.182	0.061	0.228
	Glycosylphosphatidylinositol(GPI)-anchor biosynthesis	14	1	0.017	4.054	0.496	0.044
	Linoleic acid metabolism	15	1	0.019	3.985	0.496	0.001
	alpha-Linolenic acid metabolism	29	1	0.036	3.332	0.715	0.001
LBD vs HC	Glycerophospholipid metabolism	39	3	0.00002	11.070	0.001	0.329
	Glycosylphosphatidylinositol(GPI)-anchor biosynthesis	14	1	0.023	3.769	0.659	0.044
	Linoleic acid metabolism	15	1	0.025	3.701	0.659	0.001
	alpha-Linolenic acid metabolism	29	1	0.047	3.050	0.835	0.001
	Glycerolipid metabolism	32	1	0.052	2.954	0.835	0.012

NSCLC, non-small cell lung cancer; LBD, lung benign disease; HC, healthy controls.